Sign In
Buy BPMC
$129.46
+0 (+0%)
At Close: Oct 17, 2025
Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
12:00pm, Tuesday, 04'th Aug 2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that, effective on August 1,
Blueprint Medicines (NASDAQ:BPMC) Is In A Strong Position To Grow Its Business
12:21pm, Saturday, 01'st Aug 2020
The analysts covering Blueprint Medicines Corporation (NASDAQ:BPMC) delivered a dose of negativity to shareholders...
Blueprint Medicines' (BPMC) Q2 Earnings Miss, Revenues Beat
03:18pm, Friday, 31'st Jul 2020
Blueprint Medicines (BPMC) posts a wider-than-expected loss but revenues beat estimates in the second quarter of 2020.
Blueprint Medicines Corporation (BPMC) CEO Jeff Albers on Q2 2020 Results - Earnings Call Transcript
03:16pm, Thursday, 30'th Jul 2020
Blueprint Medicines Corporation (NASDAQ:BPMC) Q2 2020 Earnings Conference Call July 30, 2020 08:30 AM ET Company Participants Kristin Hodous - Senior Manager, IR Jeff Albers - CEO Christy Rossi - Chie
Blueprint Medicines (BPMC) Reports Q2 Loss, Tops Revenue Estimates
12:35pm, Thursday, 30'th Jul 2020
Blueprint Medicines (BPMC) delivered earnings and revenue surprises of -9.62% and 10.36%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Recap: Blueprint Medicines Q2 Earnings
11:28am, Thursday, 30'th Jul 2020
Shares of Blueprint Medicines (NASDAQ:BPMC) remained unaffected after the company reported Q2 results.Quarterly Results Earnings per share fell 11.76% over the past year to ($2.28), which missed the e
Blueprint Medicines Reports Second Quarter 2020 Financial Results
11:00am, Thursday, 30'th Jul 2020
Blueprint Medicines Corporation (NASDAQ:BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today reported financial results and provided
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs July 29)
Abbott Laboratories (NYSE: ABT)
ABIOMED, Inc. (NASDAQ: ABMD)
Adamis Pharmaceuticals Corp (NASDAQ: ADMP)
Annexon...
Theratechnologies NASH Data And Other News: The Good, Bad And Ugly Of Biopharma
04:41am, Sunday, 26'th Jul 2020
Theratechnologies announces positive report for tesamorelin in NASH. Blueprint reports positive EU response for GIST treatment.
The Week Ahead In Biotech: Spotlight On GW Pharma, Ultragenyx FDA Decisions, Pfizer Earnings
12:00am, Sunday, 26'th Jul 2020
Biotech stocks moved lower in the week ended July 26, as the broader market weakness and sector-specific developments pressured stocks.
Although there were promising updates from...
Covid-19 Takes Its Toll, But Roche Still Attractive For Longer-Term Investors
01:30pm, Friday, 24'th Jul 2020
Roche saw a bigger than expected hit to pharmaceutical sales from Covid-19, the diagnostic business continues to lag peers, but good cost-cutting preserved the core earnings performance.
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that the European Medicines
Blueprint Medicines to Report Second Quarter 2020 Financial Results on Thursday, July 30, 2020
12:00pm, Thursday, 23'rd Jul 2020
Blueprint Medicines Corporation (NASDAQ: BPMC), a precision therapy company focused on genomically defined cancers, rare diseases and cancer immunotherapy, today announced that it will host a live con
Blueprint Medicines (NASDAQ:BPMC) PT Raised to $95.00 at Deutsche Bank
05:38am, Sunday, 19'th Jul 2020
Blueprint Medicines (NASDAQ:BPMC) had its price objective hoisted by Deutsche Bank from $85.00 to $95.00 in a research report report published on Wednesday, The Fly reports. The brokerage currently ha
Wedbush Brokers Boost Earnings Estimates for Blueprint Medicines Corp (NASDAQ:BPMC)
01:34am, Saturday, 18'th Jul 2020
Blueprint Medicines Corp (NASDAQ:BPMC) – Wedbush boosted their Q2 2020 earnings per share estimates for Blueprint Medicines in a research report issued on Tuesday, July 14th. Wedbush analyst D. Nier
